Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good overview of what the company has going for it:
It has taken me about a year, but I have finally averaged down from about $1 to .10, after going through a RS or two, etc. I'm confident now that I will make money in this thing.
I just reviewed the RSPI pipeline, now for the 10th time in the past few months. I continue to be impressed with the diversity of applications of the drugs they are testing. Not all the eggs are in one basket, as in many biopharmas. Trying to add more here.
Incredible accumulation. 500k blocks trading. Wow. This has been going on for 2 days now.
The BID is way up ...CDEL wants SHARES... this will and is about to MOVE very quickly.. hold them tight folks. LEVEL 2 shows it all.
Hold those shares tight ... just need volume and it will take off. Recommend to go to Companies Website or email Jeff Margolis to see if they can update for the Month of March.
--
I just did both , asking if that can be done and get an update from CEO Tim Jones also on his progress. He has the background to do it !
https://www.linkedin.com/in/tim-jones-63493219/
Need to pop and stay in double digits
Foolish sellers this is about to take off
--
MM's want you to sell into the BID and are working it. Hold , Lock in at higher prices .. patience !!
This is encouraging. Strong activity prior to any actual significant update. Should partnership or funding announcement happen soon, this will really go up.
I agree. This is probably my best "lottery ticket".
RSPI: What is not to like here.
-
Mgt top notch, OTCQB tier level stock in OTC LAND, and with Tim Jones coming on as President (Expert in Field) and now long term employment contract , more to come . Check it out here
--
https://www.linkedin.com/in/tim-jones-63493219/
https://www.otcmarkets.com/stock/RSPI/profile
Would love for this to show the strength that it showed yesterday.
$1+ seems very possible
.25 seems possible to me.
Interesting Aurora Capital with RSPI
--
$RSPI , correction here is Jeff Margolis at RSPI
--
https://www.linkedin.com/in/jeff-margolis-b501114/
---
Also Aurora Capital.. note the Mergers and acquisitions.
http://www.auroracapital.com/services_corporateFinance.htm
Wrong Jeff Margolis .. two different people I see , similar backgrounds.
--
The connections here are immense , crazy share structure Dr. Lippa connected and the Mgt Team has the networks.
--
Got on board last week here.
--
How does Jeff Margolis being with the Blackstone Group ... connect here at RSPI if I can ask, since he was appointed to the Advisory position there this January.
--
Thanks
--
https://www.blackstone.com/press-releases/article/blackstone-announces-appointment-of-jeff-margolis-leading-healthcare-information-technology-executive-as-senior-advisor/
Judas Priest! This is amazing. I've been in this one a long time, so I deserve this. LOL.
IMO, some institutions are getting onboard.
That's what I was thinking $RSPI
Someone or someone’s got tipped off? Good news coming?
BOOM CHACKALACKA BOOM $Rspi
Finally breaking through .05. IMO, we should see a quarter in the next few months.
Cheapies getting scooped up in low .04’s again
Another 5 million and we will be ready to rock , next week the RSPI train will be pulling out
Accumulation everyday is a good thing here , we are basing for a nice run to .17 than .75+
We just can't seem to break .05. But we will.
Lotsa buys sometimes cooking $RSPI
What's the point of these small sales and buys bringing the pps down 10-14% per day?
Loading at this level is a good idea in my opinion. The entire market is falling right now, settling back into normal levels. I think it's a good idea to secure positions and wait it out.
I loaded some today.. couldn't resist $rspi
Do you mean post RS highs? I think we just came out of an rs.
Waiting for news and pre R/S highs... it’s coming
Maybe, there was a lot of chatter last year regarding future events.
Lot of buyers today, significant news could be on the way...
What are you thinking, what is your pps prediction here?
She's primed for Epic run $Rspi
More action this morning. At some point, this should explode. Only about 80M shares O/S.
I have 514,000 if it starts to go up I’ll buy more
Diamond hands my friend diamond hands will go down together or make a ton of money together
I'm committed (or maybe I should be committed, ha). I have 500,000 shares.
Followers
|
352
|
Posters
|
|
Posts (Today)
|
233
|
Posts (Total)
|
49293
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody powerbattles fly_fisherman archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |